Global Benchmark for Efficient Drug Pricing (GLOBE) Model

rall drug costs in the U.S. are primarily driven by originator, single source drugs or sole source biological products. Based on the high spending by OM Part B and Medicare Part B beneficiaries on single source drugs and sole source biological products, in this final rule, we finalized the GLOBE Model to test the impact of using international drug pricing information as a benchmark for an alternative Medicare Part B drug inflation rebate amount calculation for a subset of Part B rebatable drugs (certain single source drugs and sole source biological products that meet the criteria defined in Sec. 513.130) to reduce [[Page 62956]] Medicare program expenditures while preserving or enhancing quality of care. --------------------------------------------------------------------------- \115\ The Commonwealth Fund. U.S. Health Care from a Global Perspective, 2026, May 2026. Available at: https://www.commonwealthfund.org/publications/issue-briefs/2026/may/us-health-care-global-perspective-2026 . --------------------------------------------------------------------------- CMS notes that the scope of the model is limited to approximately 25 percent of OM Part B beneficiaries and a subset of Part B rebatable drugs that meet certain criteria, as described in section II.B. of this final rule, and that, as noted previously, the model operates for the purpose of evaluating whether an alternati